2,021 reports of this reaction
2.2% of all SUNITINIB MALATE reports
#9 most reported adverse reaction
NEOPLASM PROGRESSION is the #9 most commonly reported adverse reaction for SUNITINIB MALATE, manufactured by Pfizer Laboratories Div Pfizer Inc. There are 2,021 FDA adverse event reports linking SUNITINIB MALATE to NEOPLASM PROGRESSION. This represents approximately 2.2% of all 93,209 adverse event reports for this drug.
SUNITINIB MALATE has an overall safety score of 85 out of 100. Patients taking SUNITINIB MALATE who experience neoplasm progression should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
NEOPLASM PROGRESSION is a less commonly reported adverse event for SUNITINIB MALATE, but still significant enough to appear in the safety profile.
In addition to neoplasm progression, the following adverse reactions have been reported for SUNITINIB MALATE:
The following drugs have also been linked to neoplasm progression in FDA adverse event reports:
NEOPLASM PROGRESSION has been reported as an adverse event in 2,021 FDA reports for SUNITINIB MALATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
NEOPLASM PROGRESSION accounts for approximately 2.2% of all adverse event reports for SUNITINIB MALATE, making it a notable side effect.
If you experience neoplasm progression while taking SUNITINIB MALATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.